Pioneering personalized neuropsychiatric treatment
Cyclerion (cyclerion.com) earns a Brand Analyzer score of 68 out of 100, placing it in the Developing tier among Healthcare brands. Among 4154 Healthcare brands analyzed, Cyclerion ranks in the 29th percentile (category average 73, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 93/100, Digital Presence 91/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 77/100, AI Discoverability 37/100, Brand Authority 12/100.
Cyclerion is a biopharmaceutical company headquartered in Cambridge, United States, founded in 2018. It focuses on developing a new pipeline of therapeutics for neuropsychiatric diseases, with an initial emphasis on individualized treatment for treatment-resistant depression. The company combines therapies with validated modes of action with a technology-enabled, personalized biofeedback-driven delivery system intended to reset dysregulated brainwave patterns, aiming to address unmet needs in mental health treatment for patients and healthcare providers.
| Brand Name | Cyclerion |
|---|---|
| Domain | cyclerion.com |
| Industry | Healthcare |
| Founded | 2018 |
| Headquarters | Cambridge, United States |
| Main Competitors | Sage Therapeutics (76/100), Axsome Therapeutics (76/100), Compass Pathways (86/100), Janssen Pharmaceuticals (84/100), Neuronetics (61/100), Click Therapeutics (78/100) |
Moz Domain Authority 35/100 vs category average 37 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "To advance a new pipeline of therapeutics for neuropsychiatric diseases, beginning with individualized treatment for treatment-resistant depression." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram; no detected presence on Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Cyclerion scores 29/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Cyclerion has a weak AI-visibility profile at 29/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (53/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 35/100 and thin schema.org structured data. In a live check, Claude could already identify Cyclerion from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Cyclerion?", Claude could identify the brand as of August 2026. Cyclerion Therapeutics is a clinical-stage biopharmaceutical company spun off from Ironwood Pharmaceuticals in 2019, focused on developing soluble guanylate cyclase (sGC) stimulators to treat serious diseases including those affecting the central nervous system and other conditio Best known for Developing sGC stimulator drug candidates, originally spun out of Ironwood Pharmaceuticals.
When asked "Best brands similar to Cyclerion?", Claude would not surface Cyclerion as of August 2026. It's a fairly small, specialized clinical-stage biopharma company, so I'd only mention it in a niche context like sGC stimulator research rather than as a general recommendation.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Cyclerion's main competitors include Sage Therapeutics, Axsome Therapeutics, Compass Pathways, Janssen Pharmaceuticals, Neuronetics. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Popular alternatives to Cyclerion include Sage Therapeutics, Axsome Therapeutics, Compass Pathways, Janssen Pharmaceuticals, Neuronetics. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Cyclerion has limited AI-search visibility, scoring 29/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 22, recommendation 53). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Cyclerion official site
Cyclerion was founded in 2018. Cyclerion operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Cyclerion and Sage Therapeutics are competitors in Healthcare. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Cyclerion scores 53/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Cyclerion official site
Cyclerion offers a pipeline of therapeutics for neuropsychiatric diseases, specifically an individualized treatment for treatment-resistant depression. This treatment combines therapies with validated modes of action with a technology-enabled, personalized biofeedback-driven delivery system intended to reset dysregulated brainwave patterns.
Sources: Cyclerion official site
Cyclerion is a biopharmaceutical company based in Cambridge, United States, founded in 2018. It is developing a pipeline of therapeutics for neuropsychiatric diseases, starting with an individualized treatment approach for treatment-resistant depression.
Sources: Cyclerion official site
Cyclerion develops therapeutics for neuropsychiatric diseases, with an initial focus on treatment-resistant depression. It combines therapies with validated modes of action with a technology-enabled, personalized biofeedback-driven delivery system designed to reset dysregulated brainwave patterns in patients.
Sources: Cyclerion official site
Cyclerion can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Cyclerion official site
Cyclerion's intended users are patients suffering from treatment-resistant depression, as well as healthcare providers and health systems seeking personalized mental health treatment options.
Sources: Cyclerion official site
Cyclerion is known for pursuing a personalized, tech-enabled approach to treating treatment-resistant depression, integrating validated therapeutic modes of action with biofeedback-driven delivery systems aimed at correcting dysregulated brainwave patterns.
Sources: Cyclerion official site
Ranked closest to Cyclerion: Cúratus (68/100), CredibleMind (68/100), Dai-ichi Life Việt Nam (68/100), DataWorks LLC (68/100).
A step up - brands to learn from: Zipari by mPulse (71/100), Zaina AI (71/100).
Category leader: Elsevier (96/100).